Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab

Induction immunosuppression in kidney transplantation requires a longitudinal perspective that extends beyond early rejection prevention to encompass longterm graft durability and patient safety. In response to the recent propensity score-matched study by Chukwu et al, complementary considerations are provided that address two underrecognized dimensions: Cumulative immunological burden and the downstream interaction between induction strategies and maintenance immunosuppression. Potent lymphocyte-depleting agents, despite comparable short-term rejection rates, are associated with a disproportionate “immunological debt” in standard-risk recipients, manifested by increased viral complications, malignancy, impaired graft function, and inferior death-censored graft survival. In contrast, non-lymphocyte-depleting induction preserves immune competence while maintaining adequate rejection control in this population. The integration of strict risk stratification, extended surveillance protocols, and dynamic reassessment of maintenance immunosuppression into standardized induction pathways is essential to optimize long-term outcomes. Framing induction therapy as a long-term commitment rather than a perioperative intervention supports alignment of immunosuppressive intensity with recipient risk and sustained graft stewardship.